RxDoctor Payments DataLook up a doctor →

Don Dubose, MD

Child & Adolescent Psychiatry · Columbia, SCNPI 1336313329

Payments from drug & device makers

$289,602in general payments, 2019–2025

Across 756 payments — averaging $383.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$238K
  • AbbVie$47K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$556
  • Supernus Pharmaceuticals, Inc.$421
  • Tris Pharma Inc$393
  • Takeda Pharmaceuticals U.S.A., Inc.$334
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$8,0803%
  • Speaking & faculty fees$233,76381%
  • Travel & lodging$35,30412%
  • Food & beverage$12,4564%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$289,602 in reported general payments places this provider in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.

See all child & adolescent psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$142,767
Medicare patients
102
Services billed
1,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl192$227,200
Venlafaxine Hcl ErVenlafaxine Hcl18$241
Quetiapine Fumarate18$151
Mirtazapine12$115
Temazepam12$51
Lorazepam18$46
Alprazolam ErAlprazolam12$45
Alprazolam11$36
Clonazepam12$33
Cyclobenzaprine Hcl11$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$238,132$227,200192 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.

Other child & adolescent psychiatry in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →